» Articles » PMID: 31625042

At Odds About the Odds: Women's Choices to Accept Osteoporosis Medications Do Not Closely Agree with Physician-Set Treatment Thresholds

Overview
Publisher Springer
Specialty General Medicine
Date 2019 Oct 19
PMID 31625042
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Osteoporosis guidelines recommend pharmacologic therapy based on 10-year risk of major osteoporotic fracture (MOF) and hip fracture, which may fail to account for patient-specific experiences and values.

Objective: We aimed to determine whether patient decisions to initiate osteoporosis medication agree with guideline-recommended intervention thresholds.

Design And Participants: This prospective cohort study included women aged ≥ 45 with age-associated osteoporosis who attended a group osteoporosis self-management consultation at a tertiary osteoporosis center.

Intervention: A group osteoporosis self-management consultation, during which participants received osteoporosis education and then calculated their 10-year MOF and hip fracture risk using FRAX and their predicted absolute fracture risk with therapy (assuming 40% relative reduction). Participants then made autonomous decisions regarding treatment initiation.

Main Measures: We evaluated agreement between treatment decisions and physician-set intervention thresholds (10-year MOF risk ≥ 20%, hip fracture risk ≥ 3%).

Key Results: Among 85 women (median [IQR] age 62 [58-67]), 27% accepted treatment (median [IQR] MOF risk, 15.1% [9.9-22.0]; hip fracture risk, 3.3% [1.3-5.3]), 46% declined (MOF risk, 9.5% [6.5-11.6]; hip fracture risk, 1.8% [0.6-2.3]), and 27% remained undecided (MOF risk, 14.0% [9.8-20.2]; hip fracture risk, 4.4% [1.7-4.9]). There was wide overlap in fracture risk between treatment acceptors and non-acceptors. Odds of accepting treatment were higher in women with prior fragility fracture (50% accepted; OR, 5.3; 95% CI, 1.9-15.2; p = 0.0015) and with hip fracture risk ≥ 3% (32% accepted; OR, 3.6; 95% CI, 1.4-9.2; p = 0.012), but not MOF risk ≥ 20% (47% accepted; OR, 3.0; 95% CI, 1.0-8.5; p = 0.105).

Conclusions: Informed decisions to start osteoporosis treatment are highly personal and not easily predicted using fracture risk. Guideline-recommended intervention thresholds may not permit sufficient consideration of patient preferences.

Citing Articles

How Should Clinicians Discuss Deprescribing with Caregivers of Older Adults Living with Dementia? A Qualitative Study.

Fasth L, Kelley C, Colon-Emeric C, Green A, Thorpe C, Gilliam M Drugs Aging. 2025; 42(2):155-164.

PMID: 39827439 PMC: 11848725. DOI: 10.1007/s40266-024-01179-w.


Decision threshold models in medical decision making: a scoping literature review.

Scarffe A, Coates A, Brand K, Michalowski W BMC Med Inform Decis Mak. 2024; 24(1):273.

PMID: 39334341 PMC: 11429414. DOI: 10.1186/s12911-024-02681-2.


Development of a program theory for osteoporosis patient education in Denmark: a qualitative study based on realist evaluation.

Rubaek M, Broholm-Jorgensen M, Andersen S, Jakobsen P, Rothmann M, Langdahl B BMC Geriatr. 2024; 24(1):346.

PMID: 38627654 PMC: 11022455. DOI: 10.1186/s12877-024-04957-8.


Deprescribing bisphosphonates for older adults with dementia: perspectives of caregivers.

Niznik J, Kelley C, Fasth L, Colon-Emeric C, Thorpe C, Gilliam M Osteoporos Int. 2023; 35(4):589-598.

PMID: 37980284 PMC: 11145563. DOI: 10.1007/s00198-023-06967-5.


Women's perspectives regarding osteoporosis, fracture risk, and pharmacologic treatment: a cross-sectional study.

Billington E, Miyagishima R, Hasselaar C, Arain M Osteoporos Int. 2023; 34(12):2069-2076.

PMID: 37608123 DOI: 10.1007/s00198-023-06890-9.


References
1.
Modi A, Sajjan S, Insinga R, Weaver J, Lewiecki E, Harris S . Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years. Osteoporos Int. 2017; 28(4):1355-1363. DOI: 10.1007/s00198-016-3886-y. View

2.
Majumdar S, Lier D, Hanley D, Juby A, Beaupre L . Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS. Osteoporos Int. 2017; 28(6):1965-1977. PMC: 5486946. DOI: 10.1007/s00198-017-3986-3. View

3.
Neuner J, Schapira M . The importance of physicians' risk perception in osteoporosis treatment decision making. J Clin Densitom. 2011; 15(1):49-54. DOI: 10.1016/j.jocd.2011.07.008. View

4.
Montori V, Shah N, Pencille L, Branda M, Van Houten H, Swiglo B . Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med. 2011; 124(6):549-56. DOI: 10.1016/j.amjmed.2011.01.013. View

5.
Solomon D, Johnston S, Boytsov N, McMorrow D, Lane J, Krohn K . Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014; 29(9):1929-37. PMC: 4258070. DOI: 10.1002/jbmr.2202. View